EC Number   |
Application |
Reference |
|---|
  3.5.1.60 | drug development |
inhibitors against N-acylethanolamine-hydrolyzing acid amidase are promising tools against bladder cancer |
752960 |
| 3.5.1.60 | drug development |
NAAA is a promising target for the development of effective and safe treatments for atopic dermatitis and other inflammatory disorders of the skin |
-, 754356 |
| 3.5.1.60 | drug development |
the cysteine hydrolase, N-acylethanolamine acid amidase (NAAA) is a promising target for analgesic and anti-inflammatory drugs |
753248 |
| 3.5.1.60 | drug development |
the enzyme is a target for drug design |
734845 |
| 3.5.1.60 | medicine |
modulation of the tissue levels of palmitoylethanolamide by inhibition of enzymes responsible for the breakdown of this lipid mediator, including the N-acylethanolamine acid amidase, may represent therefore a therapeutic strategy for the treatment of pain and inflammation |
734845 |
| 3.5.1.60 | pharmacology |
NAAA inhibitor F215 is a therapeutic agent for osteoarthritis. The therapeutic effects of F215 are blocked by the PPAR-alpha antagonist MK886 |
755003 |
| 3.5.1.60 | pharmacology |
potential of blocking N-acylethanolamines like palmitoylethanolamide or N-arachidonlyethanolamine (anandamide) from enzymatic degradation via enzyme inhibition as a strategy for pain treatment |
734562 |
